Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis

YALÇIN, Tuğba; BAL HASTÜRK, AJDA; Cakci, Aytul; ERKOÇ, Sibel; ERDOĞDU DÜLGEROĞLU, Deniz; KARAAHMET, Özgür

Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis

Deniz ERDOĞDU DÜLGEROĞLU, (Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Fiziksel Tıp ve Rehabilitasyon Kliniği, Ankara, Türkiye)

AJDA BAL HASTÜRK, (Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Fiziksel Tıp ve Rehabilitasyon Kliniği, Ankara, Türkiye)

Özgür KARAAHMET, (Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Fiziksel Tıp ve Rehabilitasyon Kliniği, Ankara, Türkiye)

Sibel ERKOÇ, (Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Fiziksel Tıp ve Rehabilitasyon Kliniği, Ankara, Türkiye)

Tuğba YALÇIN, (Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Fiziksel Tıp ve Rehabilitasyon Kliniği, Ankara, Türkiye)

Aytül ÇAKCI (Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Fiziksel Tıp ve Rehabilitasyon Kliniği, Ankara, Türkiye)

Archives of Rheumatology

1 0

Yıl: 2014 Cilt: 29 Sayı: 4 Sayfa Aralığı: 257 - 266 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis

Öz:

Amaç: Bu çalışmada ankilozan spondilit tedavisinde infliksimab, etanersept ve adalimumab gibi tümör nekroz faktör-alfa blokerlerinin etkinliğinin araştırılması amaçlanmıştır. Hastalar ve yöntemler: Kliniğimizde son dokuz yıl içinde tedavi edilen 59 ankilozan spondilit hastasının tümör nekroz faktör-alfa bloker tedavisinin sonuçları retrospektif olarak incelendi. Hastaların Uluslararası Spondilartrit Değerlendirme Derneği (ASAS) 20 ve ASAS 40 yanıt oranları, ilaç yan etkileri ve tedaviye uyumları değerlendirildi. Bulgular: Üçüncü ayda hastaların %89.8i, altıncı ayda %93.2si ASAS 20 yanıtına ulaştı. Üçüncü ve altıncı ayda hastaların %61i ASAS 40 yanıtına ulaştı. Tümör nekroz faktör-alfa blokerlerinin üçü arasında ASAS 40 yanıt oranı açısından istatistiksel olarak anlamlı fark bulunmadı. Hastaların 31inde gözlenen hafif enfeksiyonlar en yaygın yan etkiydi. Ciddi yan etki sadece bir hastada gözlendi. Çeşitli nedenlerden dolayı tedaviden çekilen hastaların sayısı altıydı. Sonuç: İnfliksimab, etanersept veya adalimumab ile tedavi klinik olarak etkili ve güvenlidir.

Anahtar Kelime:

Konular: Romatoloji

Ankilozan spondilit hastalarında tümör nekroz faktör inhibitörlerinin etkinliği

Öz:

Objectives: This study aims to investigate the efficacy of tumor necrosis factor-alpha blockers such as infliximab, etanercept, and adalimumab in the treatment of ankylosing spondylitis. Patients and methods: The outcome of tumor necrosis factor-alpha blocker treatment was analyzed retrospectively in 59 patients with ankylosing spondylitis who were being treated in our clinic during last nine years. The patients Assessment of SpondyloArthritis International Society (ASAS) 20 and ASAS 40 response rates, adverse drugs effects, and treatment compliance were evaluated. Results: ASAS 20 response was achieved by 89.8% of the patients in the third month, and by 93.2% in the sixth month. ASAS 40 response was achieved by 61% of the patients in the third and sixth month. No statistically significant difference was detected between the three tumor necrosis factor-alpha blockers with regards to the ASAS 40 response rates. Mild infections, observed in 31 of the patients, were the most common side effects. Serious side effect was observed in only one patient. The number of patients who withdrew from the treatment for various reasons was six. Conclusion: Treatment with infliximab, etanercept, or adalimumab is clinically effective and safe.

Anahtar Kelime:

Konular: Romatoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Toussirot E, Bertolini E, Wending D Management of ankilosing spondylitis with infliximab. Open Access Rheumatology Research and Reviews 2009;1:69-82.
2. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005;44:670-6.
3. Paul S, Keat A. Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor alpha blockade. Rheumatology (Oxford) 2005;44:17-23.
4. Bodur H, Sivas F, Yılmaz Ö, Özgöçmen S, Günaydın R, Kaya T, et al. Turkish League against Rheumatism National Recommendations for the management of ankylosing spondylitis. Turk J Rheumatol 2011;26:173-86.
5. Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford) 2008;47:897-900.
6. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
7. Dougados M, Braun J, Szanto S, Combe B, Geher P, Leblanc V, et al. Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. Rheumatology (Oxford) 2012;51:1687-96.
8. Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011;70:973-81.
9. Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. Rheumatology (Oxford) 2011;50:1690-9.
10. Baraliakos X, van den Berg R, Braun J, van der Heijde D. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/ EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford) 2012;51:1378-87.
11. Maksymowych WP. Update on the treatment of ankylosing spondylitis. Ther Clin Risk Manag 2007;3:1125-33.
12. Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) 2005;44:1525-30.
13. Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 2005;53:856-63.
14. van der Heijde D, Landewé R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-70.
15. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005;64:1462-6.
16. van der Heijde DM, Revicki DA, Gooch KL, Wong RL, Kupper H, Harnam N, et al. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 2009;11:R124.
17. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
18. Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 2006;65:1147-53.
19. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
20. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
21. Ay S, Kutlay , Kurtayi Y, Yanık B. Ankilozan spondilitli hastalarda Bath Ankilozan Spondilit Hastalk

APA	ERDOĞDU DÜLGEROĞLU D, BAL HASTÜRK A, KARAAHMET Ö, ERKOÇ S, YALÇIN T, Cakci A (2014). Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis. , 257 - 266.
Chicago	ERDOĞDU DÜLGEROĞLU Deniz,BAL HASTÜRK AJDA,KARAAHMET Özgür,ERKOÇ Sibel,YALÇIN Tuğba,Cakci Aytul Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis. (2014): 257 - 266.
MLA	ERDOĞDU DÜLGEROĞLU Deniz,BAL HASTÜRK AJDA,KARAAHMET Özgür,ERKOÇ Sibel,YALÇIN Tuğba,Cakci Aytul Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis. , 2014, ss.257 - 266.
AMA	ERDOĞDU DÜLGEROĞLU D,BAL HASTÜRK A,KARAAHMET Ö,ERKOÇ S,YALÇIN T,Cakci A Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis. . 2014; 257 - 266.
Vancouver	ERDOĞDU DÜLGEROĞLU D,BAL HASTÜRK A,KARAAHMET Ö,ERKOÇ S,YALÇIN T,Cakci A Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis. . 2014; 257 - 266.
IEEE	ERDOĞDU DÜLGEROĞLU D,BAL HASTÜRK A,KARAAHMET Ö,ERKOÇ S,YALÇIN T,Cakci A "Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis." , ss.257 - 266, 2014.
ISNAD	ERDOĞDU DÜLGEROĞLU, Deniz vd. "Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis". (2014), 257-266.

APA	ERDOĞDU DÜLGEROĞLU D, BAL HASTÜRK A, KARAAHMET Ö, ERKOÇ S, YALÇIN T, Cakci A (2014). Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis. Archives of Rheumatology, 29(4), 257 - 266.
Chicago	ERDOĞDU DÜLGEROĞLU Deniz,BAL HASTÜRK AJDA,KARAAHMET Özgür,ERKOÇ Sibel,YALÇIN Tuğba,Cakci Aytul Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis. Archives of Rheumatology 29, no.4 (2014): 257 - 266.
MLA	ERDOĞDU DÜLGEROĞLU Deniz,BAL HASTÜRK AJDA,KARAAHMET Özgür,ERKOÇ Sibel,YALÇIN Tuğba,Cakci Aytul Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis. Archives of Rheumatology, vol.29, no.4, 2014, ss.257 - 266.
AMA	ERDOĞDU DÜLGEROĞLU D,BAL HASTÜRK A,KARAAHMET Ö,ERKOÇ S,YALÇIN T,Cakci A Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis. Archives of Rheumatology. 2014; 29(4): 257 - 266.
Vancouver	ERDOĞDU DÜLGEROĞLU D,BAL HASTÜRK A,KARAAHMET Ö,ERKOÇ S,YALÇIN T,Cakci A Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis. Archives of Rheumatology. 2014; 29(4): 257 - 266.
IEEE	ERDOĞDU DÜLGEROĞLU D,BAL HASTÜRK A,KARAAHMET Ö,ERKOÇ S,YALÇIN T,Cakci A "Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis." Archives of Rheumatology, 29, ss.257 - 266, 2014.
ISNAD	ERDOĞDU DÜLGEROĞLU, Deniz vd. "Efficacy of tumor necrosis factor ınhibitors in patients with ankylosing spondylitis". Archives of Rheumatology 29/4 (2014), 257-266.